Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
NCT00791518 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1084
Last updated 2014-07-30
Summary
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
No intervention
No intervention
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-12-31
- Primary Completion
- 2009-05-31
- Completion
- 2009-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837 ·Status: RECRUITING ·Phase: PHASE1
-
Study of GSK961081 in Healthy Volunteer Subjects
NCT00887406 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
NCT00559910 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
NCT00984659 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01001494 ·Status: COMPLETED ·Phase: PHASE3
-
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
NCT02130193 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT00363896 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
NCT01391559 ·Status: COMPLETED ·Phase: NA
-
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
NCT00783406 ·Status: COMPLETED ·Phase: PHASE2
-
Symbicort in Chronic Obstruktive Pulmonary Disease
NCT00612976 ·Status: COMPLETED
-
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
NCT01045161 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
NCT01005901 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01119950 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00690482 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
NCT00501852 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
NCT02743013 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
NCT01049360 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmaceutical Care for Chronic Obstructive Pulmonary Disease (COPD) Study.
NCT01260389 ·Status: COMPLETED ·Phase: NA
-
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT01572792 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
NCT00749411 ·Status: COMPLETED ·Phase: PHASE2
-
NVA237 BID Versus Placebo Twelve-week Efficacy Study
NCT01715298 ·Status: COMPLETED ·Phase: PHASE3
-
Symbicort in Chronic Obstructive Pulmonary Disease
NCT00611520 ·Status: COMPLETED
-
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
NCT01387230 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT01120093 ·Status: COMPLETED ·Phase: PHASE2